摘要
目的观察重组人白介素-11、环孢素A联合糖皮质激素治疗免疫性血小板减少症(ITP)的临床疗效。方法随机数字法将80例ITP患者分为观察组与对照组,每组40例。观察组采取重组人白介素11、环孢素A联合糖皮质激素治疗,对照组给予环孢素A联合糖皮质激素治疗,比较两组临床疗效及安全性,并测定记录治疗前后血小板计数(PLT)、外周血白介素-4(IL-4)、干扰素-γ(IFN-γ)及T细胞亚群相关指标。结果观察组治疗总有效率95.00%显著高于对照组的80.00%(P<0.05);与治疗前比较,两组治疗第4天、第14天、第1个月、第4个月PLT均显著上升,治疗结束后IFN-r、CD8^+显著下降,CD3^+、CD4^+、CD4^+/CD8^+均显著上升,差异有统计学意义(P<0.05),且观察组治疗后上述指标均明显优于对照组(P<0.05);两组均无肝肾功能异常等明显不良反应发生。结论重组人白介素11、环孢素A联合糖皮质激素治疗ITP安全有效,能明显改善T淋巴细胞亚群指标。
Objective To observe the clincial efficacy of recombinant human interleukin- 11 and cyclosporine A combined with glucocorticoids in treatment of immune thrombocytopenia（ ITP）. Methods Eighty patients with ITP were randomly divided into observation group and control group,40 cases in each group. Patients in observation group were treated with recombinant human interleukin 11 and cyclosporine A combined with glucocorticoids while patients in control group were treated with cyclosporine A combined with glucocorticoids. The results of clinical efficacy and safety were compared between these two groups. The platelet count（ PLT）,peripheral blood interleukin- 4（ IL- 4）,interferon- γ（ IFN- γ） and T cell subsets associated indicators were determined and recorded before and after treatment. Results The total effective rate in patients of observation group（ 95. 00%） was significantly higher than that of control group（ 80. 00%）（ P〈0. 05）. On the 4th day,14 th day,1st month and 4th month of treatment,the amount of PLT in both groups was significantly higher than that before treatment. After treatment,levels of IFN- γ and CD8^ ＋ were significantly decreased while CD3^＋,CD4^＋and CD4^＋/ CD8^＋were significantly increased（ P〈0. 05）. After treatment,the indexes in observation group were significantly better than those of control group（ P〈0. 05）. There was no obvious adverse reactions such as abnormal liver and kidney function in both groups. Conclusion The application of recombinant human interleukin 11 and cyclosporine A combined with glucocorticoids is safe and effective in the treatment of ITP,which can significantly improve T cell subsets.
出处
《临床和实验医学杂志》
2016年第23期2322-2325,共4页
Journal of Clinical and Experimental Medicine
基金
江苏省卫生厅科技计划项目(编号:2012-FJ3026)
